Torrent Pharmaceuticals L
NSE: TORNTPHARM · Pharmaceuticals · sector
₹4,550.00NSE close 2026-10-26
Key numbers
Market cap₹1,53,999 cr
Price₹4,550.00
52w high / low₹5,250 / ₹3,533
P/E72.7xSector median 27.9x
P/B18.4xSector median 2.9x
Book value₹247.9
Dividend yield0.84%Sector median 0.48%
ROE27.3%Sector median 11.7%
ROCE15.1%Sector median 12.3%
OPM32.3%Sector median 14.0%
Debt / equity1.76xSector median 0.16x
EV/EBITDA32.8xSector median 18.6x
Interest cover5.5x
Current ratio1.13x
Sales growth 3y+13.3%Sector median +9.6%
Profit growth 3y+20.2%Sector median +13.3%
PEG3.60x
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹2,031 cr vs borrowings ₹14,798 cr (FY26): borrowings are higher by ₹12,767 cr.
- Operating profit covered interest 5.5x in the last 12 months.
- No promoter shares are pledged.
- Promoter holding fell by 7.53 percentage points in a year, to 60.78% (2026-09-30).
- Operating cash flow was below net profit in 0 of the last 5 years.
- Revenue was higher than a year earlier in 4 of the last 4 quarters.
- Other income was -3% of net profit in the last 12 months.
- Debtor days went from 63 (FY24) to 79 (FY26).
- Dividend paid in 5 of the last 5 financial years.
- Price ₹4,550.00 on 2026-10-26: -13.3% from the 52-week high, +28.8% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹5,033.40 · low ₹2,959.25
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2,889 | 2,809 | 2,959 | 3,178 | 3,302 | 3,303 | 4,197 | 4,921 |
| EBITDA | 939 | 914 | 940 | 1,032 | 1,070 | 1,078 | 1,290 | 1,643 |
| OPM % | 32.5% | 32.5% | 31.8% | 32.5% | 32.4% | 32.6% | 30.7% | 33.4% |
| Other income | -16 | 33 | -18 | -37 | -27 | -13 | -17 | -12 |
| Net profit | 453 | 503 | 498 | 548 | 591 | 635 | 389 | 566 |
| EPS (₹) | 13.37 | 14.88 | 14.71 | 16.19 | 17.45 | 18.77 | 11.51 | 14.87 |
| Revenue YoY | +14.3% | +17.6% | +41.8% | +54.8% | ||||
| Profit YoY | +30.5% | +26.2% | -21.9% | +3.3% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 8,508 | 9,620 | 10,728 | 11,516 | 13,980 | 15,723 |
| EBITDA | 1,946 | 2,842 | 3,456 | 3,697 | 4,470 | 5,081 |
| Net profit | 777 | 1,245 | 1,656 | 1,911 | 2,163 | 2,181 |
| EPS (₹) | 45.93 | 36.79 | 48.94 | 56.47 | 63.92 | 62.60 |
| Revenue growth | +13.1% | +11.5% | +7.3% | +21.4% | +32.9% | |
| Profit growth | +60.2% | +33.0% | +15.4% | +13.2% | +8.9% | |
| Dividend / share (₹) | 40.00 | 14.00 | 30.00 | 32.00 | 35.00 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +13.3% | +11.8% | +32.9% |
| Net profit | +20.2% | +11.6% | +8.9% |
| EPS | +20.2% | -2.9% | – |
| Share price | – | +15.9% (2y) | +26.8% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 6,198 | 6,856 | 7,591 | 8,389 |
| Borrowings | – | 5,297 | 3,938 | 3,026 | 14,798 |
| Cash & equivalents | – | 727 | 980 | 691 | 2,031 |
| Total assets | – | 15,012 | 15,061 | 14,990 | 44,312 |
| Fixed assets | – | 2,772 | 3,297 | 3,455 | 4,909 |
| Capital work in progress | – | 688 | 281 | 367 | 457 |
| Investments | – | 43 | 32 | 44 | 83 |
| Receivables | – | 1,944 | 1,844 | 1,867 | 3,031 |
| Inventory | – | 2,230 | 2,279 | 2,541 | 3,138 |
| Payables | – | 1,679 | 2,089 | 1,820 | 2,358 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 1,803 | 2,368 | 3,266 | 2,585 | 3,023 |
| Cash from investing | -198 | -2,356 | -168 | -540 | -12,713 |
| Cash from financing | -1,781 | 77 | -2,779 | -2,298 | 10,151 |
| Capex | 203 | 574 | 433 | 611 | 677 |
| Free cash flow | 1,600 | 1,794 | 2,833 | 1,974 | 2,346 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | 20.1% | 24.2% | 25.2% | 25.8% |
| ROCE % | – | 19.0% | 25.1% | 27.6% | 14.0% |
| Debtor days | – | 74 | 63 | 59 | 79 |
| Inventory days | – | 298 | 310 | 334 | 338 |
| Payable days | – | 224 | 284 | 239 | 254 |
| Cash conversion cycle (days) | – | 148 | 89 | 154 | 163 |
| Working capital days | – | -5 | 6 | 29 | 27 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 60.78% |
| FIIs | 17.22% |
| DIIs | 13.46% |
| of which Mutual funds | 8.82% |
| of which Insurance | 1.96% |
| Government | 0.00% |
| Public (non-institutions) | 8.54% |
| Quarter | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Jul 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 68.31% | 68.31% | 68.31% | 68.31% | 68.31% | 68.31% | 60.78% | 60.78% |
| Promoter group | % |
|---|---|
| Torrent Investments Limited (Formerly Known AS Torrent Investments Private Limited) | 60.78% |
| Sudhir Uttamlal Mehta | 0.00% |
| Samir Uttamlal Mehta | 0.00% |
| Anita Sudhir Mehta | 0.00% |
| Sapna Samir Mehta | 0.00% |
| Jinal Sudhir Mehta | 0.00% |
| Varun Sudhir Mehta | 0.00% |
| Shaan Mehta | 0.00% |
| Aman Mehta | 0.00% |
| Mehta Family Trust 1 | 0.00% |
| Mehta Family Trust 2 | 0.00% |
| Mehta Family Trust 3 | 0.00% |
| Mehta Family Trust 4 | 0.00% |
| Radiant Urja LLP | 0.00% |
| Abhivyakti Enterprise LLP | 0.00% |
| Public holders above 1% | % |
|---|---|
| NPS Trust | 2.32% |
| HDFC Mutual Fund | 1.14% |
| Axis Mutual Fund Trustee Limited A/C Axis Mutual Fund | 1.12% |
| Kotak Debt Hybrid | 1.05% |
1,42,140 shareholders. Pledged: 0.00% of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| LUPIN | ₹89,616 cr | 16.2x | 4.0x | 27.9% | 27.9% | 30.0% | +18.9% | 0.61% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-05-29 | Dividend | Dividend - Rs 9 Per Share |
| 2026-02-18 | Dividend | Interim Dividend - Rs 29 Per Share |
| 2025-06-20 | Dividend | Dividend - Rs 6 Per Share |
| 2025-01-31 | Dividend | Interim Dividend - Rs 26 Per Sh |
| 2024-06-21 | Dividend | Dividend - Rs 6 Per Share |
| 2024-02-12 | Dividend | Interim Dividend - Rs 22 Per Share |
| 2023-06-23 | Dividend | Dividend - Rs 8 Per Share |
| 2023-02-03 | Dividend | Interim Dividend - Rs 14 Per Share |
| 2022-07-08 | Bonus | Bonus 1:1 |
| 2022-02-02 | Dividend | Interim Dividend - Rs 25 Per Share |
| 2021-06-17 | Dividend | Dividend - Rs 15 Per Share |
| 2021-02-15 | Dividend | Interim Dividend - Rs 20 Per Share |
| 2020-03-18 | Dividend | Interim Dividend - Rs 17 Per Share Special Dividend - Rs 15 Per Share |
| 2019-06-13 | Dividend | Dividend Rs 4 Per Share |
| 2019-02-06 | Dividend | Interim Dividend - Rs 13 Per Share |
| 2018-06-18 | Dividend | Dividend- Rs 5 Per Share |
| 2018-02-15 | Dividend | Interim Dividend Rs 9/- Per Share (Purpose Revised) |
| 2017-06-19 | Dividend | Dividend - Rs 4/- Per Share |
| 2017-02-10 | Dividend | Interim Dividend Rs 10/- Per Share (Purpose Revised) |
| 2016-03-16 | Dividend | Interim Dividend - Rs 15/- Per Share (Purpose Revised) |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- BRSR FY26
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- Research & Development, Manufacturing, Marketing, and Distribution of Pharmaceutical Products: We are one of the leading pharmaceutical companies in India and are engaged in research, development, manufacturing, marketing and distribution of branded and generic pharmaceutical formulations in India and Internationally.
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | TORNTPHARM |
| BSE code | 500420 |
| ISIN | INE685A01028 |
| Face value | ₹5.0 |
| Incorporated | 1972-07-15 |
| Website | www.torrentpharma.com |
| Plants (India / abroad) | 9 / 0 |
From the company's filings (BRSR FY26).
Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.